Divi's Laboratories Limited (DIVISLAB) — Board Meeting | 7 November 2025

· NSE 🟡 Notable ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Divi's Laboratories reported Q2 FY2025-26 standalone revenue of ₹2,660 crores (up 12.8% QoQ from ₹2,357 crores) with profit after tax of ₹696 crores (up 25% QoQ). H1 FY2025-26 delivered ₹5,017 crores revenue and ₹1,253 crores PAT. Consolidated Q2 results showed ₹2,860 crores total income and ₹689 crores PAT, with YoY growth of 17% and 35% respectively. The board promoted Nimmagadda Venkata Anirudh to President (Nutraceuticals) effective November 7, 2025.

📄 View Original Announcement (PDF)

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

📊 More DIVISLAB filings

See all DIVISLAB filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DIVISLAB — Free

Free account · 2 AI queries/day